Quick Answer
BIOMARIN PHARMACEUTICAL INC reported Revenue (ASC 606) of $3.22 billion for fiscal year 2025.
BIOMARIN PHARMACEUTICAL INC Revenue (ASC 606) — Annual History
| Fiscal Year | Revenue (ASC 606) | YoY Change |
|---|---|---|
| 2025 | $3.22B | +12.9% |
| 2024 | $2.85B | +18.0% |
| 2023 | $2.42B | +15.4% |
| 2022 | $2.10B | +13.5% |
| 2021 | $1.85B | -0.8% |
| 2020 | $1.86B | +9.2% |
| 2019 | $1.70B | +14.3% |
| 2018 | $1.49B | +13.5% |
| 2017 | $1.31B | +17.6% |
| 2016 | $1.12B | — |
Quarterly Revenue (ASC 606)
| Quarter Ending | Revenue (ASC 606) | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $776.13M | +4.1% | -6.0% |
| June 30, 2025 | $825.41M | +15.9% | +10.8% |
| March 31, 2025 | $745.14M | +14.8% | -0.1% |
| September 30, 2024 | $745.74M | +28.3% | +4.7% |
| June 30, 2024 | $712.03M | +19.6% | +9.7% |
| March 31, 2024 | $648.83M | +8.8% | +11.6% |
| September 30, 2023 | $581.33M | +15.0% | -2.3% |
| June 30, 2023 | $595.27M | +11.5% | -0.2% |
- BIOMARIN PHARMACEUTICAL INC showed an increase of +12.9% in Revenue (ASC 606) compared to the prior fiscal year.
- Over the 2016–2025 period, BIOMARIN PHARMACEUTICAL INC’s revenue (asc 606) has grown by 188.4% (from $1.12 billion to $3.22 billion).
- The most recent figure is from BIOMARIN PHARMACEUTICAL INC’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: